LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Search

Penumbra Inc

Gesloten

SectorGezondheidszorg

287.42 -1.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

286.03

Max

293.25

Belangrijke statistieken

By Trading Economics

Inkomsten

581K

46M

Verkoop

15M

355M

K/W

Sectorgemiddelde

69.443

80.03

Winstmarge

12.927

Werknemers

4,500

EBITDA

4M

55M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+5.57% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.6B

11B

Vorige openingsprijs

288.81

Vorige sluitingsprijs

287.42

Nieuwssentiment

By Acuity

50%

50%

162 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Penumbra Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 dec 2025, 17:29 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dec 2025, 16:21 UTC

Winsten

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dec 2025, 16:18 UTC

Winsten

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dec 2025, 23:53 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dec 2025, 22:48 UTC

Winsten

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dec 2025, 22:12 UTC

Marktinformatie

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dec 2025, 22:03 UTC

Marktinformatie

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dec 2025, 21:56 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

2 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 dec 2025, 21:44 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 21:38 UTC

Marktinformatie

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dec 2025, 21:19 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 20:06 UTC

Marktinformatie

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dec 2025, 19:55 UTC

Marktinformatie

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dec 2025, 19:53 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

2 dec 2025, 19:53 UTC

Marktinformatie
Winsten

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dec 2025, 19:24 UTC

Marktinformatie

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dec 2025, 19:06 UTC

Marktinformatie

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dec 2025, 18:27 UTC

Acquisities, Fusies, Overnames

Kraken to Acquire Backed Finance AG

2 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 dec 2025, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 dec 2025, 15:17 UTC

Marktinformatie

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dec 2025, 14:47 UTC

Marktinformatie

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dec 2025, 14:38 UTC

Marktinformatie

Silver Steps Back From Record Levels -- Market Talk

2 dec 2025, 14:31 UTC

Marktinformatie
Winsten

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Peer Vergelijking

Prijswijziging

Penumbra Inc Prognose

Koersdoel

By TipRanks

5.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 307.92 USD  5.57%

Hoogste 355 USD

Laagste 266 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Penumbra Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

288.28 / 292.9394Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

162 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat